Myriad Genetics (MYGN) Reports In-Line Q2 EPS, misses on revenue, provides guidance
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $4.33 -6.48%
EPS Growth %: -220.0%
Financial Fact:
Total costs and expenses: 171.3M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: -220.0%
Financial Fact:
Total costs and expenses: 171.3M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $183.5 million versus the consensus estimate of $187.07 million.
GUIDANCE:
Myriad Genetics sees FY2023 EPS of ($0.36)-($0.24). Myriad Genetics sees FY2023 revenue of $730-750 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- The Lovesac Company (LOVE) Tops Q1 EPS by 29c
- Oxford Industries (OXM) Tops Q1 EPS by 12c; Offers Outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
